GlassScriptPhysician profile
Robyn M Moore
NPI 1669907028
$6,647.14
in general payments reported to CMS, 2019-2025
35 companies · $3,649 in 2025
The $3,649 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $905 · 2023: $812 · 2024: $608 · 2025: $3,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,991.80 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,002.98 | 2021-2025 | Saphnelo, Fasenra, Airsupra |
| Abbvie INC. | $892.67 | 2021-2025 | |
| Amgen INC. | $804.47 | 2024-2025 | Tavneos, Krystexxa, Repatha |
| Abbott Laboratories | $465.72 | 2023-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $336.94 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Biotech, INC. | $280.17 | 2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $259.11 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $206.63 | 2022-2023 | Camzyos |
| Lundbeck LLC | $167.33 | 2025 | Rexulti |
| Mallinckrodt Hospital Products INC. | $152.93 | 2025 | Acthar |
| Genzyme Corporation | $133.16 | 2025 | |
| Tempus Ai, INC | $124.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.07 | 2022 | |
| Exeltis, USA INC. | $123.98 | 2025 | |
| Novo Nordisk INC | $123.11 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $119.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Paratek Pharmaceuticals, INC. | $113.06 | 2025 | Nuzyra |
| Antares Pharma, INC. | $112.63 | 2022 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Coloplast Corp | $110.55 | 2023 | Titan, Altis |
| Averitas Pharma INC. | $110.41 | 2023 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $102.68 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $96.66 | 2022 | |
| Esperion Therapeutics, INC. | $79.20 | 2021 | |
| Glaxosmithkline, LLC. | $72.73 | 2025 | Benlysta |
| Pfizer INC. | $63.53 | 2025 | |
| Ani Pharmaceuticals, INC. | $56.86 | 2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $48.58 | 2025 | Tymlos |
| Biocon Biologics INC | $39.23 | 2025 | Yesintek |
| Hospira, INC. | $24.80 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.56 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.59 | 2025 | |
| Genentech USA, INC. | $16.32 | 2025 | Actemra |
| Sandoz INC. | $16.26 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.